A new weight loss pill, orforglipron, has helped patients shed up to 20% of their body weight in a major trial, raising hopes of a more accessible alternative to injections such as Wegovy and Mounjaro.
The once-daily pill, developed by Eli Lilly, was tested on more than 3,100 adults with obesity across nine countries. After 72 weeks, nearly one in five participants on the highest dose lost at least a fifth of their body weight, while over half saw reductions of 10% or more. Patients also recorded improvements in blood pressure, cholesterol, and waist size.
Unlike injectable GLP-1 agonists, orforglipron could be easier to distribute, store, and afford, potentially broadening access to obesity treatments. The most common side effects were mild to moderate stomach issues.
The results, published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes, come ahead of expected high demand once the pill secures regulatory approval.
Researchers say the tablet could expand obesity treatment options for millions currently unable to access costly injections. Meanwhile, new studies suggest GLP-1 drugs may also benefit children, though more research is needed on long-term safety.
